Results 71 to 80 of about 5,702,542 (372)

Extramedullary plasmacytoma: Tumor occurrence and therapeutic concepts—A follow‐up

Cancer Medicine, Volume 11, Issue 24, Page 4743-4755, December 2022., 2022
This paper provides an overview of the extramedullary plasmacytoma cases reported between 1999 and 2021. The global patients’ cohort and the current therapy options are compared to our previous report from 1999. Abstract Background Extramedullary plasmacytoma (EMP) is a solitary tumor consisting of neoplastic plasma cells, with very little to no bone ...
Adrian Holler, Iwona Cicha, Markus Eckstein, Marlen Haderlein, Marina Pöttler, Anja Rappl, Heinrich Iro, Christoph Alexiou   +7 more
wiley   +1 more source

High-Order Fiber Mode Beam Parameter Optimization for Transport and Rotation of Single Cells

Micromachines, 2021
Optical tweezers are becoming increasingly important in biomedical applications for the trapping, propelling, binding, and controlled rotation of biological particles.
Zihao Shan, Shunnan Yao, Enfan Zhang, Dun Pi, Wen Cao, Feng Lin, Zhen Cai, Xingkun Wu   +7 more
doaj   +1 more source

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Journal of Clinical Investigation, 2019
BACKGROUND Chimeric antigen receptor (CAR) T cells are a promising therapy for hematologic malignancies. B-cell maturation antigen (BCMA) is a rational target in multiple myeloma (MM).
Adam D. Cohen, A. Garfall, E. Stadtmauer, J. Melenhorst, S. Lacey, E. Lancaster, D. Vogl, Brendan M. Weiss, Karen Dengel, A. Nelson, G. Plesa, Fang Chen, M. Davis, W. Hwang, R. Young, J. Brogdon, R. Isaacs, Iulian Pruteanu-Malinici, Don L. Siegel, Bruce L. Levine, Carl H. June, Michael C. Milone   +21 more
semanticscholar   +1 more source

CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.

Radiology, 2020
Background Current measurements of multiple myeloma disease burden are suboptimal. Daratumumab is a monoclonal antibody that targets CD38, an antigen expressed on nearly all myeloma cells. Purpose To demonstrate preclinical and first-in-human application
G. Ulaner, Nicholas Sobol, J. O’Donoghue, A. Kirov, C. Riedl, Ryan Min, E. Smith, L. Carter, S. Lyashchenko, Jason S. Lewis, C. Landgren   +10 more
semanticscholar   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)

Advances in Hematology, 2022
Of the variety of immunoglobulin related amyloidosis (AL), immunoglobulin M (IgM) related AL represents only 6 to 10% of affected patients, and the majority of these cases are associated with underlying non-Hodgkin’s Lymphoma including Waldenström’s ...
Maroun Bou Zerdan, Jason Valent, Maria Julia Diacovo, Karl Theil, Chakra P. Chaulagain   +4 more
doaj   +1 more source

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Haematologica, 2023
To improve the outcomes of patients with the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of ...
Paul G. Richardson, Brian G. Durie, Laura Rosiñol, Maria-Victoria Mateos, Angela Dispenzieri, Philippe Moreau, Shaji Kumar, Noopur Raje, Nikhil Munshi, Jacob P. Laubach, Peter O’Gorman, Elizabeth O’Donnell, Peter Voorhees, Thierry Facon, Joan Bladé, Sagar Lonial, Aurore Perrot, Kenneth C. Anderson   +17 more
doaj   +1 more source

CD44v, S1PR1, HER3, MET and cancer‐associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb

FEBS Open Bio, EarlyView.
Novel mAbs could detect cancer‐associated membrane proteins on various type of pancreatic ductal adenocarcinomas (PDAC) by flow cytometry with viable PDAC cells and by immunohistochemistry with PDAC tissues. Results of protein expression were substantiated by mRNA expression by The Cancer Genome Atlas.
Takashi Nakano, Kouki Okita, Shogo Okazaki, Soshi Yoshimoto, Sachiko Masuko, Hideki Yagi, Kazunori Kato, Yoshihisa Tomioka, Kenichi Imai, Yoichi Hamada, Kazue Masuko, Kayoko Shimada‐Takaura, Noriaki Nagai, Hideyuki Saya, Tomio Arai, Toshiyuki Ishiwata, Takashi Masuko   +16 more
wiley   +1 more source

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

Nature Communications
Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood.
Jiye Liu, Lijie Xing, Jiang Li, Kenneth Wen, Ning Liu, Yuntong Liu, Gongwei Wu, Su Wang, Daisuke Ogiya, Tian-Yu Song, Keiji Kurata, Johany Penailillo, Eugenio Morelli, Tingjian Wang, Xiaoning Hong, Annamaria Gulla, Yu-Tzu Tai, Nikhil Munshi, Paul Richardson, Ruben Carrasco, Teru Hideshima, Kenneth C. Anderson   +21 more
doaj   +1 more source

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

Frontiers in Immunology, 2018
The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM ...
Shih-Feng Cho, Shih-Feng Cho, Shih-Feng Cho, Shih-Feng Cho, Kenneth C. Anderson, Kenneth C. Anderson, Yu-Tzu Tai, Yu-Tzu Tai   +7 more
doaj   +1 more source